GlassScriptPhysician profile
Robin S Hiser
NPI 1982098018
$7,442.08
in general payments reported to CMS, 2019-2025
22 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,263 · 2022: $3,186 · 2023: $616 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,033 · Food and Beverage: $930 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,033.00 |
| Food and Beverage | $929.96 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,111.73 | 2021-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $1,192.01 | 2021-2023 | |
| Janssen Biotech, INC. | $985.80 | 2021-2022 | |
| Horizon Therapeutics Plc | $631.39 | 2021-2023 | Krystexxa |
| Ucb, INC. | $502.27 | 2021-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $318.93 | 2021-2023 | Orencia |
| Mallinckrodt Hospital Products INC. | $279.72 | 2021-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $259.08 | 2021-2023 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $258.70 | 2021-2023 | |
| Lilly USA, LLC | $219.83 | 2021-2023 | Taltz |
| Pfizer INC. | $185.16 | 2021-2023 | |
| Glaxosmithkline, LLC. | $106.98 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.55 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $61.77 | 2022-2023 | Purified Cortrophin Gel |
| Biogen, INC. | $60.00 | 2025 | Tysabri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $44.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $31.23 | 2022 | |
| Genentech USA, INC. | $28.98 | 2021 | |
| Genzyme Corporation | $19.85 | 2021 | |
| Sobi, INC | $18.78 | 2023 | |
| Celgene Corporation | $15.11 | 2021 | |
| Pacira Therapeutics, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.